New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 2, 2024 - Fresenius Kabi announced the launch of Tyenne (tocilizumab-aazg) subcutaneous formulation, a biosimilar to Roche’s Actemra (tocilizumab).
Download PDF
Return to publications
